Directory of Pharma Companies and News
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofiâ€™s programs in oncology and immunology.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|2018-11-29||Sanofi builds focus on rare blood disorders and cancers|
|2018-11-06||FDA grants priority review for DupixentÂ® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-t...|
|2018-10-19||KevzaraÂ® (sarilumab) data at the 2018 ACR/ARHP Annual Meeting provide additional insight on safety, efficacy in rheumato...|
|2018-10-19||FDA approves asthma indication for DupixentÂ® (dupilumab)|
|2018-10-16||DupixentÂ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with...|
|2018-10-10||Sanofi Presents 8-Year Data on LemtradaÂ® (Alemtuzumab)|
|2018-10-10||Sanofi presents new data on AubagioÂ® (teriflunomide)|
|2018-10-08||LibtayoÂ® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation|
|2018-10-08||More Than 30 Data Presentations from Sanofi Genzymeâ€™s Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Co...|
|2018-09-28||FDA approves LibtayoÂ® (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma|